Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tasquinimod - Active Biotech

Drug Profile

Tasquinimod - Active Biotech

Alternative Names: ABR-215050; TASQ

Latest Information Update: 21 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Ipsen
  • Class Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma; Prostate cancer

Highest Development Phases

  • Preclinical Multiple myeloma
  • Discontinued Gastric cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 14 Feb 2019 The US Patent Office grants patent for tasquinimod for the treatment of Multiple Myeloma, before February 2019 .
  • 14 Feb 2019 Active Biotech signs agreement with Wistar Institute for clinical development of tasquinimod in Multiple myeloma, before February 2019
  • 14 Feb 2019 The US Patent Office approves patent application for tasquinimod for the treatment of Acute leukaemia, before February 2019 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top